📰 Erasca Mapklamp News

Erasca Mapklamp News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Erasca Mapklamp. Real-time updates on events, politics, business and more.

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination

November 30, 2022

ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated in combination with encorafenib and cetuximab in BRAF V600E-mutant metastatic colorectal cancer Erasca previously signed...

United States South Korea Pierre Fabre Asia Pacific Erasca Mapklamp Eli Lilly

Source: marketscreener.com

Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials

September 7, 2022

23% of patients with RAS/MAPK-altered non-CRC solid tumors and 44% with BRAF-driven non-CRC solid tumors responded to single agent ERAS-007 or ERAS-601 ERAS-007 and ERAS-601 had favorable... | September 7, 2022

United States Wei Lin Erasca Mapklamp Joyce Allaire Exchange Commission Lifesci Advisors

Source: marketscreener.com

Erasca to Host R&D Day with KOL Dr. David Hong on Lead

August 24, 2022

Virtual event on Wednesday, September 7 at 4:30 PM ET will feature key opinion leader (KOL) David Hong, M.D., from MD Anderson Cancer Center Company to...

United States Jesseh Jones David Hong Erasca Mapklamp Joyce Allaire Davids Hong

Source: globenewswire.com

Erasca Announces Trial to Evaluate ERAS-007 in Combination

June 2, 2022

Proof-of-concept data from trial may support addition of ERAS-007 as a treatment option to overcome RAS/MAPK resistance to KRAS G12C inhibitors...

United States Bryan Corcoran Scott Kopetz Erasca Mapklamp Joyce Allaire Lifesci Advisors